孫曉東

（河北省廊坊市人民醫(yī)院，河北 廊坊 065000）

匹多莫德聯(lián)合左氧氟沙星預(yù)防女性反復(fù)泌尿系感染復(fù)發(fā)100例

孫曉東

（河北省廊坊市人民醫(yī)院，河北 廊坊 065000）

目的 評(píng)估匹多莫德聯(lián)合氟喹諾酮類(lèi)藥物預(yù)防女性泌尿系感染復(fù)發(fā)的有效性和安全性。方法 200例復(fù)發(fā)性泌尿系感染患者治愈后，隨機(jī)均分為對(duì)照組和治療組，各100例。對(duì)照組患者給予小劑量左氧氟沙星抑菌治療，每次0．1 g，每日1次；治療組患者在對(duì)照組治療基礎(chǔ)上加用匹多莫德片治療，每次0．4 g，每日1次。兩組患者均治療6個(gè)月并隨訪6個(gè)月，比較泌尿系感染復(fù)發(fā)率。結(jié)果 治療組患者在治療期間、隨訪期前3個(gè)月、隨訪期后3個(gè)月感染復(fù)發(fā)率分別為5．00%，10．00%，11．00%，分別低于對(duì)照組的8．00%，19．00%，21．00%（P＜0．05）。治療過(guò)程中，治療組和對(duì)照組患者不良反應(yīng)發(fā)生率分別為3．00%和2．00%，無(wú)顯著性差異。結(jié)論 匹多莫德聯(lián)合氟喹諾酮類(lèi)藥物可以有效預(yù)防女性泌尿系感染的復(fù)發(fā)，且無(wú)明顯不良反應(yīng)，值得臨床推廣。

匹多莫德；氟喹諾酮類(lèi)；泌尿系感染；復(fù)發(fā)性；女性

復(fù)發(fā)性泌尿系感染的患者多見(jiàn)于體質(zhì)較差的青年育齡婦女、老年女性、糖尿病等自身免疫力較差的患者，急性期抗菌治療后臨床多采取低劑量氟喹諾酮類(lèi)藥物抑菌治療，但臨床治療效果欠佳。匹多莫德為免疫調(diào)節(jié)劑，可有效提高患者的免疫功能，目前也常用于泌尿系感染的輔助治療，但對(duì)其用于復(fù)發(fā)性泌尿系感染患者的系統(tǒng)研究尚未見(jiàn)報(bào)道。為此，本研究觀察了匹多莫德聯(lián)合氟喹諾酮預(yù)防女性復(fù)發(fā)性泌尿系感染的有效性和安全性，為臨床治療提供參考。

Clinical Observation of Pidotimod plus Levofloxacin for Preventing Female Recurrent Urinary Tract Infection in 100 Cases

Sun Xiaodong
(Langfang Municipal People′s Hospital,Langfang,Hebei,China 065000)

Objective To evaluate the efficacy and safety of pidotimod plus fluoroquinolones in the prevention of female recurrent urinary tract infection．M ethods 200 patients with recurrent urinary tract infection after cure were randomly divided into two groups,100 cases in each group．The control group took low dose of levofloxacin 0．1 g,once daily;while on this basis the treatment group was added with Pidotimod Tablet 0．4 g，once daily．The two groups were treated for 6 months and followed up for 6 months．The relapsing rates of urinary system infection were compared between the two groups．Results The relapsing rates during the treatment period in the first 3 months of follow-up and the late 3 months of follow-up in the treatment group were 5．00%,10．00% and 11．00% respectively, which were lower than 8．00%,19．00% and 21．00% in the control group(P＜0．05)．The occurrence rates of adverse reactions during the treatment process in the treatment group and the control group were 3．00% and 2．00% respectively,but the differences had no statistical significance．Conclusion Pidotimod combined with fluoroquinolones can effectively prevent the recurrence of female urinary tract infection without obvious adverse reactions and deserves to be clinically promoted．

pidotimod;fluoroquinolones;urinary system infection;relapse;female

R969.4；R979.5

A

1006-4931(2015)05-0046-02